Atara Current Deferred Revenue from 2010 to 2024
| ATRA Stock | USD 12.18 0.08 0.65% |
Current Deferred Revenue | First Reported 2010-12-31 | Previous Quarter 77.8 M | Current Value 81.7 M | Quarterly Volatility 28.8 M |
Check Atara Biotherapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Atara Biotherapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 4.8 M, Selling General Administrative of 47.3 M or Other Operating Expenses of 196.3 M, as well as many indicators such as Price To Sales Ratio of 6.02, Dividend Yield of 0.0 or Days Sales Outstanding of 1.5 K. Atara financial statements analysis is a perfect complement when working with Atara Biotherapeutics Valuation or Volatility modules.
Atara | Current Deferred Revenue |
Latest Atara Biotherapeutics' Current Deferred Revenue Growth Pattern
Below is the plot of the Current Deferred Revenue of Atara Biotherapeutics over the last few years. It is revenue that has been collected but not yet earned, typically from prepaid service contracts or subscriptions. This amount is considered a liability until the service is provided or the subscription period ends. Atara Biotherapeutics' Current Deferred Revenue historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Atara Biotherapeutics' overall financial position and show how it may be relating to other accounts over time.
| Current Deferred Revenue | 10 Years Trend |
|
Current Deferred Revenue |
| Timeline |
Atara Current Deferred Revenue Regression Statistics
| Arithmetic Mean | 17,249,910 | |
| Coefficient Of Variation | 166.73 | |
| Mean Deviation | 22,531,880 | |
| Median | (500,000) | |
| Standard Deviation | 28,761,516 | |
| Sample Variance | 827.2T | |
| Range | 82.2M | |
| R-Value | 0.78 | |
| Mean Square Error | 353.2T | |
| R-Squared | 0.60 | |
| Significance | 0.0007 | |
| Slope | 4,996,134 | |
| Total Sum of Squares | 11581.1T |
Atara Current Deferred Revenue History
About Atara Biotherapeutics Financial Statements
Atara Biotherapeutics stakeholders use historical fundamental indicators, such as Atara Biotherapeutics' Current Deferred Revenue, to determine how well the company is positioned to perform in the future. Although Atara Biotherapeutics investors may analyze each financial statement separately, they are all interrelated. For example, changes in Atara Biotherapeutics' assets and liabilities are reflected in the revenues and expenses on Atara Biotherapeutics' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Atara Biotherapeutics. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Current Deferred Revenue | 77.8 M | 81.7 M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Atara Biotherapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Atara Biotherapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Atara Biotherapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Atara Biotherapeutics Stock:Check out the analysis of Atara Biotherapeutics Correlation against competitors. For information on how to trade Atara Stock refer to our How to Trade Atara Stock guide.You can also try the Insider Screener module to find insiders across different sectors to evaluate their impact on performance.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Atara Biotherapeutics. If investors know Atara will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Atara Biotherapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (25.32) | Revenue Per Share 12.263 | Quarterly Revenue Growth 28.927 | Return On Assets (0.57) | Return On Equity (20.15) |
The market value of Atara Biotherapeutics is measured differently than its book value, which is the value of Atara that is recorded on the company's balance sheet. Investors also form their own opinion of Atara Biotherapeutics' value that differs from its market value or its book value, called intrinsic value, which is Atara Biotherapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Atara Biotherapeutics' market value can be influenced by many factors that don't directly affect Atara Biotherapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Atara Biotherapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Atara Biotherapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Atara Biotherapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.